Aprotinin (Trasylol)

Subscribe to Selected New Research on Aprotinin

1329 relevant articles (137 outcomes, 184 trials/studies) found for this Drug

Description: A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Also Known As:

Trasylol; Antilysin; Arzneimittelwerk Dresden Brand of Aprotinin; Bayer Brand of Aprotinin; Bovine Pancreatic Trypsin Inhibitor; Contrical; Contrykal; Dilmintal; Iniprol; Kontrikal; Kontrykal; Pulmin; Sanofi Winthrop Brand of Aprotinin; Traskolan; Zymofren; Inactivator, Kallikrein-Trypsin; Kallikrein Trypsin Inactivator; BPTI, Basic Pancreatic Trypsin Inhibitor; Basic Pancreatic Trypsin Inhibitor; Bovine Kunitz Pancreatic Trypsin Inhibitor; Kallikrein-Trypsin Inactivator; Kunitz Pancreatic Trypsin Inhibitor; Trypsin Inhibitor, Basic, Pancreatic; Trypsin Inhibitor, Kunitz, Pancreatic

Relationship Network

Drug Context: Research Results

Experts

1.	Augoustides, John G T: 4 articles (06/2008 - 07/2005)
2.	Dietrich, Wulf: 3 articles (10/2007 - 02/2005)
3.	Pruefer, Diethard: 3 articles (09/2007 - 11/2002)
4.	Buerke, Michael: 3 articles (09/2007 - 11/2002)
5.	Bianchi, Cesario: 3 articles (08/2005 - 10/2004)
6.	Sellke, Frank W: 3 articles (08/2005 - 10/2004)
7.	Feng, Jun: 3 articles (08/2005 - 10/2004)
8.	Voisine, Pierre: 3 articles (08/2005 - 10/2004)
9.	Khan, Tanveer A: 3 articles (08/2005 - 10/2004)
10.	Buyukbas, Sadik: 2 articles (10/2008 - 08/2007)

Related Diseases

1.	Hemorrhage 08/01/2002 - "Large-dose aprotinin was safe and effective in dramatically reducing the measured and calculated bleeding and the amount of transfused red blood cell units after major orthopedic surgery. " 02/01/2000 - "CONCLUSIONS: High-dose aprotinin was highly effective in reducing bleeding in this high-risk group of patients. " 12/01/1996 - "RESULTS: All three aprotinin doses were highly effective in reducing bleeding and transfusion requirements. " 04/01/1998 - "Aprotinin is widely used and has proven efficacy in the management of excess bleeding. " 01/01/1997 - "RESULTS: Aprotinin recipients benefited from a significant reduction in bleeding complications, and a decrease in perioperative and in-hospital mortalities as compared with untreated patients. " Order ALL the reference details at left...
2.	Postoperative Hemorrhage 09/01/1999 - "Although administered intraoperatively, aprotinin treatment dramatically reduced intraoperative and 24-h postoperative blood loss and autologous transfusion requirements but did not change homologous transfusion in posterior lumbar spine fusion. " 06/01/2004 - "Full-dose aprotinin significantly reduces postoperative blood loss and has been demonstrated in multiple prospective blinded studies to be safe and effective. " 05/01/2008 - "RESULTS: Aprotinin was associated with a significant reduction in postoperative blood loss (p < 0.001) and less excessive postoperative hemorrhage (p < 0.001) compared with the control group. " 03/01/2001 - "RESULTS: A significant reduction in postoperative blood loss (approximately 470 ml) occurred in patients receiving aprotinin. " 08/01/1994 - "CONCLUSIONS: Aprotinin inhibited fibrinolysis; this correlated with a significant reduction of postoperative blood loss and need for blood replacement after CPB. " Order ALL the reference details at left...
3.	Reperfusion Injury 06/01/1999 - "In conclusion, aprotinin at high concentrations may be beneficial for the survival of skeletal muscle and provides protection from platelet accumulation in the microcirculation of skeletal muscle exposed to ischaemia and reperfusion injury." 06/01/2000 - "CONCLUSION: When aprotinin was used, LV pressure was inclined to be higher while liver portal vein pressure was lower, thus providing protection against liver and heart reperfusion injury." 05/01/2004 - "Aprotinin ameliorates ischemia/reperfusion injury in a rat hind limb model." 02/01/2003 - "Improved myocardial function has been observed with aprotinin treatment in animal models of ischemia-reperfusion injury. " 11/01/2000 - "The enhanced oxygenation suggests that aprotinin may offer protection against early reperfusion injury." Order ALL the reference details at left...
4.	Pancreatitis 03/01/1985 - "These species differences of the aprotinin blockade should be considered when seeking reasons why aprotinin has not proven effective in preventing the morbidity and mortality of human pancreatitis." 01/01/1984 - "The efficacy of MTI on these types of pancreatitis were higher than those of aprotinin. " 09/01/1980 - "Steroid administration worsened pancreatitis, Trasylol had no effect, and albumin was markedly effective in ameliorating pancreatitis. " 05/01/1964 - "TRASYLOL: A NEW TREATMENT FOR PANCREATITIS." 12/13/1974 - "[Efficacy of trasylol in the treatment of acute pancreatitis]" Order ALL the reference details at left...
5.	Stroke (Strokes) 12/01/2004 - "Meta-analysis of clinical trials demonstrates a decreased incidence of stroke after CABG when aprotinin is administrated perioperatively. " 12/01/2006 - "In contrast, however, a recent cohort study has raised concerns about aprotinin, suggesting that its use is associated with a significant increased risk of stroke in uncomplicated CABG surgery. " 12/01/2006 - "We conclude that there is evidence from three meta-analyses and two more recent RCTs that the use of aprotinin is associated with a decreased incidence of stroke and neurological complications in some patients undergoing cardiac surgery. " 12/01/2006 - "The question addressed was whether aprotinin use was associated with a lower incidence of stroke and neurological complications in adult patients undergoing cardiac surgery. " 12/01/2006 - "Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery?" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tranexamic Acid (AMCA)
2.	Aprotinin (Trasylol)
3.	Serine Endopeptidases (Serine Protease)
4.	6-Aminocaproic Acid (6 Aminocaproic Acid)
5.	Kallikreins (Kallikrein)
6.	Protease Inhibitors (Protease Inhibitor)
7.	Aspirin (Acetylsalicylic Acid)
8.	Peptide Hydrolases (Proteases)
9.	Enzymes
10.	Sodium

Related Therapies and Procedures

1.	Cardiopulmonary Bypass (Heart-Lung Bypass)
2.	Blood Transfusion (Blood Transfusions)
3.	Transplants (Transplant)
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Liver Transplantation

Best Treatments:
Research Summary Report
on Hemorrhage

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3107 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>